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Background: Tenecteplase represents a promising alternative to alteplase as thrombolytic treatment 
in acute ischemic stroke. There is limited data on tenecteplase 0.4 mg/kg in patients with increased 
stroke severity. We aimed to assess safety and efficacy of tenecteplase 0.4 mg/kg in patients with 
moderate and severe ischemic stroke. 
Methods: NOR-TEST was a phase III trial designed to investigate safety and efficacy of tenecteplase 
0.4 mg/kg versus alteplase 0.9 mg/kg in ischemic stroke. In this post-hoc analysis, moderate stroke 
was defined as admission NIHSS 6-14 and severe stroke as NIHSS ≥15. Rates of favorable outcome at 
90 days, symptomatic intracerebral hemorrhage (sICH) and mortality after 7 and 90 days were 
assessed.  
Results: In patients with moderate stroke (n=261), there were no differences in rates favorable 
outcome, sICH or mortality between tenecteplase and alteplase. In patients with severe stroke 
(n=87) there were no differences in outcome, frequency of sICH or mortality at 7 days, but all-cause 
mortality at 90 days was increased in patients treated with tenecteplase (10 [26.3%] vs. 4 [9.1%], 
p=0.045). One patient died of sICH in the tenecteplase group and two patients died of sICH in the 
alteplase group.   
Conclusion: Rates of favorable outcome and sICH were similar between treatment groups in patients 
with moderate and severe stroke. Mortality after 90 days was increased in patients with severe 
stroke receiving tenecteplase. Future studies assessing tenecteplase 0.4 mg/kg should monitor safety 








In acute ischemic stroke, several phase II trials have shown that tenecteplase 0.1, 0.25 and 0.4 mg/kg 
may be safe and associated with favorable outcome in selected patient populations.1-4 Recently, The 
Norwegian Tenecteplase Stroke Trial (NOR-TEST) showed similar effect and safety outcomes of 0.4 
mg/kg tenecteplase as compared to alteplase 0.9 mg/kg in a more general stroke population 
including 1100 patients.5 However, a majority of patients had mild stroke.  
We aimed to assess safety and efficacy of tenecteplase 0.4 mg/kg in patients with moderate and 
severe ischemic stroke included in NOR-TEST.  
 
Methods 
The data that support the findings of this study are available from the corresponding author on 
request. NOR-TEST was a multicenter, randomized, open-label, blinded endpoint, phase III trial 
designed to investigate safety and efficacy of tenecteplase 0.4 mg/kg versus alteplase 0.9 mg/kg in 
acute ischemic stroke.5 Inclusion criteria comprised clinically suspected acute ischemic stroke eligible 
for thrombolytic treatment according to European guidelines in patients aged at least 18 years living 
independently pre-stroke and admitted within 4.5 hours of stroke onset with measurable deficits on 
NIHSS. Favorable outcome was defined as mRS 0-1. Clinical improvement was defined as an 
improvement of 4 NIHSS points within 24 hours as compared to admission NIHSS or NIHSS 0 at 24 
hours. Cause of death was based on information from serious adverse event (SAE) registration forms 
completed by local investigators.  
Patients with stroke mimics were excluded. Moderate stroke was defined as admission NIHSS 6-14 
and severe stroke as admission NIHSS ≥15.  
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NOR-TEST was performed in accordance with the guidelines for Good Clinical Practice and the 
Declaration of Helsinki and written informed consent was obtained from every patient or from close 
relatives if the patient was not able to sign.  
Statistics 
Univariate analyses were performed with student`s t-test or Mann-Whitney U test for continuous 
variables and Fisher`s exact test or chi-squared test for categorical variables as appropriate. Logistic 
regression analyses were performed with outcome variables as dependent variables and 
tenecteplase vs. alteplase as independent variable, in addition to confounders such as age, sex and 
variables with p<0.1 from univariate analyses.  
 
Results  
A total of 261 patients had moderate stroke of which 123 were treated with tenecteplase vs. 138 
with alteplase and 87 patients had severe stroke of which 40 were treated with tenecteplase vs. 47 
with alteplase (table 1).  
In patients with moderate stroke, rates of favorable outcome (tenecteplase: 58 [49.2%] vs. alteplase: 
61 [45.2%], p=0.528), sICH (5 [4.1%] vs. 3 [2.2%], (p=0.481) and mortality within 90 days (10 [8.5%] 
vs. 11 [8.3%], p=0.100) were similar in both treatment groups.  
In patients with severe stroke, rates of favorable outcome (9 [23.7%] vs. 7 [15.6%], p=0.410) and sICH 
(4 [10.0%] vs. 3 [6.4], p=0.698) were also similar in both groups. Mortality within 90 days (10 [26.3%] 
vs. 4 [9.1%], p=0.045) was increased for patients treated with tenecteplase.  
In patients with severe stroke who died within 90 days, there were no differences in median age, 
NIHSS on admission or minutes from stroke debut to thrombolytic treatment  in patients who 




There were no differences between tenecteplase vs. alteplase in rates of favorable outcome or 
clinical improvement in patients with occlusions of internal carotid artery (n=8), proximal (n=62) or 
distal (n=49) middle cerebral artery. 
Of the ten patients treated with tenecteplase who were dead within 90 days, seven patients died 
during the hospital stay, five of which due to large ischemic stroke with no effect of thrombolytic 
treatment (two patients underwent unsuccessful thrombectomy), one due to sICH and one due to 
decreasing hemoglobin, renal insufficiency and pneumonia. Three patients died after hospital 
discharge and cause of death was unknown for these patients. Of the four deceased patients treated 
with alteplase, three patients died during hospital stay, two of which due to sICH and one due to 
large ischemic stroke with no effect of thrombolytic treatment. One patient with unknown cause of 
death died after hospital discharge.    
In logistic regression analysis, tenecteplase was independently associated with death within 90 days 
(OR 6.0, 95% CI 1.2-29.4, p=0.027) after adjusting for age, sex, atherosclerotic stroke etiology and 
systolic BP on admission in patients with severe stroke.  
 
Discussion 
Our study showed that clinical outcomes were similar between tenecteplase 0.4 mg/kg vs. alteplase 
0.9 mg/kg in patients with moderate and severe ischemic stroke. Crude frequencies of favorable 
outcomes were consistently higher in patients receiving tenecteplase, yet not significantly so.  
There were no significant differences between treatment groups in rates of cerebral hemorrhages, 
although frequencies of sICH were higher in patients with both moderate and severe stroke receiving 
tenecteplase. However, crude numbers were small in both groups and the results are thus vulnerable 
to influence by chance.  
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Our study showed increased all-cause mortality within 90 days in patients with severe stroke 
receiving tenecteplase. SAE-records showed that a majority of patients died due to severe stroke that 
did not respond to thrombolytic treatment. Two patients in both treatment groups died of causes 
that may be directly related as an adverse event of thrombolytic therapy: one patient due to sICH 
and decreasing hemoglobin, renal failure and pneumonia in the tenecteplase group and two due to 
sICH in the alteplase group. Consequently, there is no definitive reason to conclude that the 
increased mortality was directly related to tenecteplase. In addition, rates of mortality were 
relatively low in the alteplase group as compared to historical data.6 Our findings of an increased 
mortality in patients with severe stroke treated with tenecteplase should, however, not be 
neglected.  
There are some limitations to our study. First, cause of death was based on reports from SAE 
registration forms completed by local investigators and may thus be inaccurate as autopsy was not 
performed. Secondly, results should be interpreted with caution due to small numbers and the 
nature of post-hoc analyses.  
In conclusion, we found similar rates of favorable outcome and sICH in patients with moderate and 
severe ischemic stroke treated with tenecteplase 0.4 mg/kg as compared to alteplase. Long-term 
mortality was increased in patients with severe stroke receiving tenecteplase. Future studies 
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Table 1: Demographic data of patients with moderate and severe ischemic stroke included in NOR-
TEST.  
 











Age, mean (SD) 69.3 (15.3) 72.6 (13.6) 0.072 73.4 (13.1) 74.3 (13.4) 0.742 
Female sex, (%) 50 (40.7) 62 (44.9) 0.486 23 (57.5) 18 (38.3) 0.088 
Risk factors, (%)       
Hypertension 57 (46.3) 72 (52.2) 0.347 19 (47.5) 24 (51.1) 0.831 
Atrial fibrillation 12 (9.8) 25 (18.1) 0.074 10 (25.0) 10 (21.3) 0.800 
Diabetes mellitus 12 (9.8) 21 (15.2) 0.185 5 (12.5) 7 (14.9) 1.000 
Clinical characteristics       
Minutes from stroke onset to 
treatment, mean (SD) 
113.2 (59.8) 114.2 (50.8) 0.889 102.7 (54.9) 96.6 (44.4) 0.580 
NIHSS on admission, median 
(IQR) 
8 (7-10) 8 (7-11) 0.391 18.5 (17-22) 18 (17-21) 0.427 
Systolic BP on admission, 
mean (SD) 
155.4 (20.7) 152.2 (22.8) 0.233 153.7 (20.9) 146.2 (20.7) 0.098 
Atherosclerotic aetiology (%) 27 (22.1) 41 (29.9) 0.155 14 (35.0) 8 (17.0) 0.082 
Cardiac aetiology (%) 33 (27.1) 37 /27.0) 0.994 14 (35.0) 22 (46.8) 0.284 
Intracranial arterial occlusion, 
(%) 
25 (20.3) 34 (24.6) 0.406 25 (62.5) 29 (61.7) 1.000 
Thrombectomy, (%) 7 (5.7) 7 (5.1) 0.825 8 (20.0) 12 (25.5) 0.615 
Clinical outcomes, (%)       
mRS 0-1 at 90 days 58 (49.2) 61 (45.2) 0.528 9 (23.7) 7 (15.6) 0.410 
Clinical improvement at 24 h 36 (29.3) 33 (23.9) 0.327 7 (17.5) 8 (17.0) 1.000 
Any ICH 12 (9.8) 18 (13.0) 0.442 14 (35.0) 10 (21.3) 0.229 
sICH 5 (4.1) 3 (2.2) 0.481 4 (10.0) 3 (6.4) 0.698 
Mortality within 7 days 3 (2.4) 3 (2.2) 1.000 6 (15.0) 2 (4.3) 0.136 
Mortality within 90 days 10 (8.5) 11 (8.3) 1.000 10 (26.3) 4 (9.1) 0.045 
NIHSS; National Institutes of Health Stroke Scale, SD; Standard deviation, mRS; modified rankin scale, IQR; 
interquartal range, BP; blood pressure, ICH; intracranial hemorrhage, sICH; symptomatic intracranial 
haemorrhage 
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